Cargando…

Hyperphosphatemia Management in Patients with Chronic Kidney Disease

Hyperphosphatemia in chronic kidney disease (CKD) patients is a potentially life altering condition that can lead to cardiovascular calcification, metabolic bone disease (renal osteodystrophy) and the development of secondary hyperparathyroidism (SHPT). It is also associated with increased prevalenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaman, Ahmed M., Kowalski, Stefan R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908098/ https://www.ncbi.nlm.nih.gov/pubmed/27330380 http://dx.doi.org/10.1016/j.jsps.2015.01.009

Ejemplares similares

The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
por: Shigematsu, Takashi, et al.
Publicado: (2012)

Hyperphosphatemia: The hidden killer in chronic kidney disease
por: Askar, Akram M.
Publicado: (2015)

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Understudied Hyperphosphatemia (Chronic Kidney Disease) Treatment Targets and New Biological Approaches
por: Anand, Ajeeta, et al.
Publicado: (2023)

Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review
por: Fishbane, Steven N., et al.
Publicado: (2021)

Phosphate intake, hyperphosphatemia, and kidney function
por: Rubio-Aliaga, Isabel, et al.
Publicado: (2022)

Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease
por: Fouque, Denis, et al.
Publicado: (2018)

Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
por: Scaria, P. Thomas, et al.
Publicado: (2009)

Targeting NaPi-IIb for Hyperphosphatemia in Chronic Kidney Disease Patients - The Dead End?
por: Apetrii, Mugurel, et al.
Publicado: (2021)

Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
por: Persy, Veerle P, et al.
Publicado: (2009)

Hyperphosphatemia and Cardiovascular Disease
por: Zhou, Chao, et al.
Publicado: (2021)

Comparison of the association intensity of creatinine and cystatin C with hyperphosphatemia and hyperparathyroidism in patients with chronic kidney disease
por: Min, Byungju, et al.
Publicado: (2023)

Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective
por: Reddy, Yogesh NV, et al.
Publicado: (2014)

Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients
por: Shin, Sooyoung, et al.
Publicado: (2014)

The Impact of Medical Nutrition Intervention on the Management of Hyperphosphatemia in Hemodialysis Patients with Stage 5 Chronic Kidney Disease: A Case Series
por: Moroșan, Elena, et al.
Publicado: (2023)

Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis
por: Zhao, Lijuan, et al.
Publicado: (2021)

Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia
por: Vallée, Michel, et al.
Publicado: (2021)

Severe Hyperphosphatemia in a Patient with Mild Acute Kidney Injury
por: Pham, Phuong Chi, et al.
Publicado: (2021)

Nutritional Guideline for the Management of Mexican Patients with CKD and Hyperphosphatemia
por: Palafox-Serdán, Frida, et al.
Publicado: (2020)

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis
por: Vasantha, J., et al.
Publicado: (2011)

Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients
por: Lenglet, Aurélie, et al.
Publicado: (2013)

Elevated Cardiac Markers in Chronic Kidney Disease as a Consequence of Hyperphosphatemia-Induced Cardiac Myocyte Injury
por: Wang, Shu, et al.
Publicado: (2014)

Severe hyperphosphatemia in a patient with chronic kidney disease and multiple myeloma–to strengthen the case toward renal replacement therapy?
por: Latus, Joerg, et al.
Publicado: (2013)

Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3–4 chronic kidney disease
por: Gao, Ying, et al.
Publicado: (2018)

Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials
por: Li, Li, et al.
Publicado: (2022)

Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy
por: Bolignano, Davide, et al.
Publicado: (2022)

Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
por: Cernaro, Valeria, et al.
Publicado: (2020)

Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease
por: Tani, Takashi, et al.
Publicado: (2017)

Hyperphosphatemia and risks of acute kidney injury, end-stage renal disease, and mortality in hospitalized patients
por: Moon, Hongran, et al.
Publicado: (2019)

Phosphate-Trapping Liposomes for Long-Term Management of Hyperphosphatemia
por: Tzror-Azankot, Chen, et al.
Publicado: (2022)

Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients
por: Nguyen, Hai V., et al.
Publicado: (2016)

Patient education for hyperphosphatemia management: Improving outcomes while decreasing costs?
por: Karavetian, Mirey, et al.
Publicado: (2018)

Association between serum fibroblast growth factor‐23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease
por: Miyakawa, Hirosumi, et al.
Publicado: (2021)

Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
por: Coyne, Daniel W., et al.
Publicado: (2022)

Npt2a as a target for treating hyperphosphatemia
por: Thomas, Linto, et al.
Publicado: (2022)

Phosphate stimulates myotube atrophy through autophagy activation: evidence of hyperphosphatemia contributing to skeletal muscle wasting in chronic kidney disease
por: Zhang, Yue-yue, et al.
Publicado: (2018)

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023)

Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence
por: Covic, Adrian, et al.
Publicado: (2013)

Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial
por: Takkavatakarn, Kullaya, et al.
Publicado: (2021)

Efficacy and Safety of Sevelamer Carbonate in Chinese Nondialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized, Double-Blind, Parallel-Group Study
por: Chen, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mqlvnjlnrpf2spkqk3e667uet8